[HAPSENG] YoY Cumulative Quarter Result on 30-Sep-2011 [#3]

Stock
[HAPSENG] HAP SENG CONSOLIDATED BHD
Announcement Date
25-Nov-2011
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2011
Quarter
30-Sep-2011 [#3]
Profit Trend
QoQ- 52.78%
YoY- 19.92%
Quarter Report
Latest QR
Upcoming QR
HAPSENG's Result
HAPSENG's Financial Summary
View:
Show?
Cumulative Result
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
Revenue 2,784,782 2,453,430 2,827,391 2,653,743 1,978,529 1,784,639 2,403,610 2.48%
PBT 787,493 574,427 465,880 470,053 332,942 141,324 509,944 7.50%
Tax -176,883 -100,873 -115,681 -113,421 -54,783 -18,972 -134,439 4.67%
NP 610,610 473,554 350,199 356,632 278,159 122,352 375,505 8.43%
-
NP to SH 565,040 445,571 300,021 263,856 220,033 92,550 325,250 9.63%
-
Tax Rate 22.46% 17.56% 24.83% 24.13% 16.45% 13.42% 26.36% -
Total Cost 2,174,172 1,979,876 2,477,192 2,297,111 1,700,370 1,662,287 2,028,105 1.16%
-
Net Worth 3,885,661 3,516,577 3,360,061 2,835,294 2,484,879 2,327,841 2,310,334 9.04%
Dividend
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
Div 505,945 330,971 97,550 75,222 33,807 28,182 28,174 61.78%
Div Payout % 89.54% 74.28% 32.51% 28.51% 15.36% 30.45% 8.66% -
Equity
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
Net Worth 3,885,661 3,516,577 3,360,061 2,835,294 2,484,879 2,327,841 2,310,334 9.04%
NOSH 2,023,782 2,068,574 2,167,781 1,928,771 563,464 563,641 563,496 23.73%
Ratio Analysis
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
NP Margin 21.93% 19.30% 12.39% 13.44% 14.06% 6.86% 15.62% -
ROE 14.54% 12.67% 8.93% 9.31% 8.85% 3.98% 14.08% -
Per Share
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
RPS 137.60 118.60 130.43 137.59 351.14 316.63 426.55 -17.17%
EPS 27.92 21.54 13.84 13.68 39.05 16.42 57.72 -11.39%
DPS 25.00 16.00 4.50 3.90 6.00 5.00 5.00 30.75%
NAPS 1.92 1.70 1.55 1.47 4.41 4.13 4.10 -11.87%
Adjusted Per Share Value based on latest NOSH - 2,085,789
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
RPS 111.85 98.54 113.56 106.59 79.47 71.68 96.54 2.48%
EPS 22.70 17.90 12.05 10.60 8.84 3.72 13.06 9.64%
DPS 20.32 13.29 3.92 3.02 1.36 1.13 1.13 61.82%
NAPS 1.5607 1.4125 1.3496 1.1388 0.9981 0.935 0.928 9.04%
Price Multiplier on Financial Quarter End Date
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
Date 30/09/14 30/09/13 28/09/12 30/09/11 30/09/10 30/09/09 30/09/08 -
Price 3.98 2.34 1.64 1.31 0.93 0.83 0.82 -
P/RPS 2.89 1.97 1.26 0.95 0.26 0.26 0.19 57.37%
P/EPS 14.26 10.86 11.85 9.58 2.38 5.05 1.42 46.85%
EY 7.02 9.21 8.44 10.44 41.99 19.78 70.39 -31.88%
DY 6.28 6.84 2.74 2.98 6.45 6.02 6.10 0.48%
P/NAPS 2.07 1.38 1.06 0.89 0.21 0.20 0.20 47.59%
Price Multiplier on Announcement Date
30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 30/09/08 CAGR
Date 26/11/14 27/11/13 29/11/12 25/11/11 24/11/10 23/11/09 28/11/08 -
Price 4.90 2.61 1.63 1.40 1.57 0.81 0.61 -
P/RPS 3.56 2.20 1.25 1.02 0.45 0.26 0.14 71.44%
P/EPS 17.55 12.12 11.78 10.23 4.02 4.93 1.06 59.61%
EY 5.70 8.25 8.49 9.77 24.87 20.27 94.62 -37.37%
DY 5.10 6.13 2.76 2.79 3.82 6.17 8.20 -7.60%
P/NAPS 2.55 1.54 1.05 0.95 0.36 0.20 0.15 60.31%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment